Literature DB >> 15278279

Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia.

K Borch-Johnsen1, S Colagiuri, B Balkau, C Glümer, B Carstensen, A Ramachandran, Y Dong, W Gao.   

Abstract

AIMS/HYPOTHESIS: In November 2003 the American Diabetes Association expert committee on the diagnosis and classification of diabetes mellitus suggested a revision of the diagnostic criteria for IFG, lowering the diagnostic threshold from 6.1 to 5.6 mmol/l. The aim of the present study was to evaluate the consequences of this change with respect to: (i) the prevalence of IFG in five different countries; (ii) the concordance between IFG and IGT (classification of individuals); and (iii) the cardiovascular risk profile of these groups. Finally we discuss the likelihood that intervention for cardiovascular risk and prevention strategies developed for individuals with IGT are applicable to subjects with IFG.
METHODS: The first part of the study is based on the population-based Danish Inter99 study, where 6265 individuals, aged 30 to 60 years and without previously diagnosed diabetes, underwent an oral glucose tolerance test. The second part is based on the DETECT-2 project, in which studies from China, India, France and USA were used to analyse the impact of the proposed revision of the diagnostic criteria in different ethnic groups.
RESULTS: The proposed change in diagnostic criteria would increase the prevalence of IFG in Denmark from 11.8 to 37.6%. The proposed IFG category would identify 60.0% of all subjects with IGT compared to 29.2% with the old criteria, but among individuals with the new IFG category only 18.5% would also have IGT. Individuals with isolated IFG had lower insulin levels and a lower cardiovascular risk profile with the proposed criteria compared with the current WHO criteria. Data from the DETECT-2 study confirmed the marked increase in the prevalence of IFG, and the estimated number of individuals in the age range 40 to 64 years with IFG in urban India, urban China and the USA would increase by 78%, 135% and 193% respectively. CONCLUSIONS/
INTERPRETATION: The proposed revised diagnostic criteria will lead to a dramatic increase in the prevalence of IFG, but the concordance rate between IFG and IGT remains low. This new IFG group will have a more favourable cardiovascular risk profile than the current IFG group as defined by the WHO. This seriously questions whether the existing intervention strategies are applicable to the new category of individuals with IFG.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278279     DOI: 10.1007/s00125-004-1468-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes.

Authors:  M M Gabir; R L Hanson; D Dabelea; G Imperatore; J Roumain; P H Bennett; W C Knowler
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

2.  IGT and IFG. Time for revision?

Authors:  K Borch-Johnsen
Journal:  Diabet Med       Date:  2002-09       Impact factor: 4.359

3.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.

Authors: 
Journal:  Diabetes Care       Date:  1997-07       Impact factor: 19.112

4.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

5.  High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey.

Authors:  A Ramachandran; C Snehalatha; A Kapur; V Vijay; V Mohan; A K Das; P V Rao; C S Yajnik; K M Prasanna Kumar; J D Nair
Journal:  Diabetologia       Date:  2001-09       Impact factor: 10.122

6.  Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe.

Authors: 
Journal:  Diabetologia       Date:  1999-06       Impact factor: 10.122

7.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

8.  Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study.

Authors:  Charlotte Glümer; Torben Jørgensen; Knut Borch-Johnsen
Journal:  Diabetes Care       Date:  2003-08       Impact factor: 19.112

9.  Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group.

Authors: 
Journal:  BMJ       Date:  1998-08-08

10.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

View more
  28 in total

1.  -to: Borch-Johnsen K, Colagiuri S, Balkau B et al. (2004) Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396-1402.

Authors:  O Vaccaro; G Riccardi
Journal:  Diabetologia       Date:  2004-11-24       Impact factor: 10.122

2.  Comment to: Borch-Johnsen K, Colagiuri S, Balkau B et al. (2004) Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396-1402.

Authors:  B Balkau; T Hillier; E Vierron; A D'Hour; P Lépinay; B Royer; C Born
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

Review 3.  There really is an epidemic of type 2 diabetes.

Authors:  S Colagiuri; K Borch-Johnsen; C Glümer; D Vistisen
Journal:  Diabetologia       Date:  2005-07-09       Impact factor: 10.122

4.  Progression from newly acquired impaired fasting glusose to type 2 diabetes.

Authors:  Gregory A Nichols; Teresa A Hillier; Jonathan B Brown
Journal:  Diabetes Care       Date:  2007-02       Impact factor: 19.112

5.  Weight change and changes in the metabolic syndrome as the French population moves towards overweight: the D.E.S.I.R. cohort.

Authors:  T A Hillier; A Fagot-Campagna; E Eschwège; S Vol; M Cailleau; B Balkau
Journal:  Int J Epidemiol       Date:  2005-12-22       Impact factor: 7.196

6.  Association of Interleukin-6 and Myeloperoxidase with Insulin Resistance in Impaired Fasting Glucose Subjects.

Authors:  Ashish Agarwal; Anupama Hegde; Charu Yadav; Afzal Ahmad; Poornima Ajay Manjrekar; Rukmini Mysore Srikantiah
Journal:  Indian J Clin Biochem       Date:  2016-05-03

Review 7.  Neuropathy in prediabetes: does the clock start ticking early?

Authors:  Nikolaos Papanas; Aaron I Vinik; Dan Ziegler
Journal:  Nat Rev Endocrinol       Date:  2011-07-12       Impact factor: 43.330

8.  New Zealand cardiovascular guidelines: best practice evidence-based guideline: the assessment and management of cardiovascular risk December 2003.

Authors:  Michael Crooke
Journal:  Clin Biochem Rev       Date:  2007-02

Review 9.  Cardiovascular risk stratification and management in pre-diabetes.

Authors:  Kristine Færch; Dorte Vistisen; Nanna Borup Johansen; Marit Eika Jørgensen
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

10.  The effect of lowering the threshold for diagnosis of impaired fasting glucose.

Authors:  So Hun Kim; Wan Sub Shim; Eun A Kim; Eun Joo Kim; Seung Hee Lee; Seong Bin Hong; Yong Seong Kim; Shin Goo Park; Jong Han Leem; Jong Whan Lim; Hun-Jae Lee; Moonsuk Nam
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.